{"success":true,"data":{"pressRelease":{"id":"175231","rtpr_id":"nGNX9tzlTf-20261021","ticker":"ROIV","exchange":"NASDAQ","all_tickers":["ROIV"],"title":"Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026","author":"Globe Newswire","published_at":"2026-10-21T11:00:00.924Z","article_body":"BASEL, Switzerland and LONDON and NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) --\nRoivant (Nasdaq: ROIV) today announced that it will host a live conference\ncall and webcast at 8:00 a.m. ET on Monday, November 9, 2026, to report its\nfinancial results for the second quarter ended September 30, 2026, and provide\na business update.\n\nTo access the conference call by phone, please register online using this\nregistration link\n(https://www.globenewswire.com/Tracker?data=4e9inWn5H9iEiMpqSVRzEOpsxld_3wJCuAvIMNmzgZ0YWyZASizGbPdy2ZWubCR7lPr8QyYYhvaeguCB7LkBtyemaQj92-LHlYVgWzMauz7t-d-XPOmF1Z5Pg2zfR9nB5Zj2hheiSceZKtSm3PZdjhEflTvQ1h27E4GVWfZg7bw=).\nThe presentation and webcast details will also be available under “Events &\nPresentations” in the Investors section of the Roivant website at\nhttps://investor.roivant.com/news-events/events. The archived webcast will be\navailable on Roivant’s website after the conference call.\n\nRoivant will also host an investor day on Wednesday, December 9, 2026. To\nattend the event in person or by webcast, please register online using this\nregistration link\n(https://www.globenewswire.com/Tracker?data=4e9inWn5H9iEiMpqSVRzEALh4gZc1_ZEL5sOzP_3eg-r1vbLokiZ652k_0cxcK7wDmGQrl-FFN6m-GRE_OkwsP8xpPBiXAYb-przEJ0gAIY_cFROWBzmLfEWlteZX4W16_hk7GV1R-swDheFZleJoA==).\nThe presentation and webcast details will also be available under “Events &\nPresentations” in the Investors section of the Roivant website at\nhttps://investor.roivant.com/news-events/events. The archived webcast will be\navailable on Roivant’s website after the conference call.\n\nAbout Roivant \nRoivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that\naims to improve the lives of patients by accelerating the development and\ncommercialization of medicines that matter. Roivant’s pipeline includes\nLISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2\nFDA-approved for the treatment of dermatomyositis in adult patients and also\nin late-stage development for the treatment of non-infectious uveitis,\ncutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human\nmonoclonal antibody targeting FcRn in development across several IgG-mediated\nautoimmune indications; and mosliciguat, an inhaled sGC activator in\ndevelopment for pulmonary hypertension associated with interstitial lung\ndisease. We advance our pipeline by creating nimble subsidiaries or\n“Vants” to develop and commercialize our medicines and technologies. For\nmore information, visit www.roivant.com.\n\nRoivant Forward-Looking Statements \nThis press release contains forward-looking statements. Statements in this\npress release may include statements that are not historical facts and are\nconsidered forward-looking within the meaning of Section 27A of the Securities\nAct of 1933, as amended (the “Securities Act”), and Section 21E of the\nSecurities Exchange Act of 1934, as amended (the “Exchange Act”), which\nare usually identified by the use of words such as “anticipate,”\n“believe,” “continue,” “could,” “estimate,” “expect,”\n“intends,” “may,” “might,” “plan,” “possible,”\n“potential,” “predict,” “project,” “should,” “would” and\nvariations of such words or similar expressions. The words may identify\nforward-looking statements, but the absence of these words does not mean that\na statement is not forward-looking. We intend these forward-looking statements\nto be covered by the safe harbor provisions for forward-looking statements\ncontained in Section 27A of the Securities Act and Section 21E of the Exchange\nAct.\n\nOur forward-looking statements include, but are not limited to, statements\nregarding our or our management team’s expectations, hopes, beliefs,\nintentions or strategies regarding the future, and statements that are not\nhistorical facts, including statements about the clinical and therapeutic\npotential of our product and product candidates, the availability and success\nof topline results from our ongoing clinical trials, the timing of potential\nregulatory approvals for our product and product candidates, any commercial\npotential of our product and product candidates following applicable\nregulatory approvals and the outcome of any pending litigation. In addition,\nany statements that refer to projections, forecasts or other characterizations\nof future events, results or circumstances, including any underlying\nassumptions, are forward-looking statements. Actual results may differ\nmaterially from those contemplated in these statements due to a variety of\nrisks, uncertainties and other factors.\n\nAlthough we believe that our plans, intentions, expectations and strategies as\nreflected in or suggested by those forward-looking statements are reasonable,\nwe can give no assurance that the plans, intentions, expectations or\nstrategies will be attained or achieved. Furthermore, actual results may\ndiffer materially from those described in the forward-looking statements and\nwill be affected by a number of risks, uncertainties and assumptions,\nincluding, but not limited to, those risks set forth in the Risk Factors\nsection of our filings with the U.S. Securities and Exchange Commission.\nMoreover, we operate in a very competitive and rapidly changing environment in\nwhich new risks emerge from time to time. These forward-looking statements are\nbased upon the current expectations and beliefs of our management as of the\ndate of this press release, and are subject to certain risks and uncertainties\nthat could cause actual results to differ materially from those described in\nthe forward-looking statements. Except as required by applicable law, we\nassume no obligation to update publicly any forward-looking statements,\nwhether as a result of new information, future events or otherwise.\n\nContacts:\nInvestors\nKeyur Parekh\nkeyur.parekh@roivant.com\n\nMedia\nStephanie Lee\nstephanie.lee@roivant.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f1a5db68-ee4f-437f-b4e6-2b840ae6a536)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9tzlTf-20261021","title":"Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026","author":"Globe Newswire","ticker":"ROIV","created":"2026-10-21T11:00:00.924Z","tickers":["ROIV"],"exchange":"NASDAQ","article_body":"BASEL, Switzerland and LONDON and NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) --\nRoivant (Nasdaq: ROIV) today announced that it will host a live conference\ncall and webcast at 8:00 a.m. ET on Monday, November 9, 2026, to report its\nfinancial results for the second quarter ended September 30, 2026, and provide\na business update.\n\nTo access the conference call by phone, please register online using this\nregistration link\n(https://www.globenewswire.com/Tracker?data=4e9inWn5H9iEiMpqSVRzEOpsxld_3wJCuAvIMNmzgZ0YWyZASizGbPdy2ZWubCR7lPr8QyYYhvaeguCB7LkBtyemaQj92-LHlYVgWzMauz7t-d-XPOmF1Z5Pg2zfR9nB5Zj2hheiSceZKtSm3PZdjhEflTvQ1h27E4GVWfZg7bw=).\nThe presentation and webcast details will also be available under “Events &\nPresentations” in the Investors section of the Roivant website at\nhttps://investor.roivant.com/news-events/events. The archived webcast will be\navailable on Roivant’s website after the conference call.\n\nRoivant will also host an investor day on Wednesday, December 9, 2026. To\nattend the event in person or by webcast, please register online using this\nregistration link\n(https://www.globenewswire.com/Tracker?data=4e9inWn5H9iEiMpqSVRzEALh4gZc1_ZEL5sOzP_3eg-r1vbLokiZ652k_0cxcK7wDmGQrl-FFN6m-GRE_OkwsP8xpPBiXAYb-przEJ0gAIY_cFROWBzmLfEWlteZX4W16_hk7GV1R-swDheFZleJoA==).\nThe presentation and webcast details will also be available under “Events &\nPresentations” in the Investors section of the Roivant website at\nhttps://investor.roivant.com/news-events/events. The archived webcast will be\navailable on Roivant’s website after the conference call.\n\nAbout Roivant \nRoivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that\naims to improve the lives of patients by accelerating the development and\ncommercialization of medicines that matter. Roivant’s pipeline includes\nLISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2\nFDA-approved for the treatment of dermatomyositis in adult patients and also\nin late-stage development for the treatment of non-infectious uveitis,\ncutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human\nmonoclonal antibody targeting FcRn in development across several IgG-mediated\nautoimmune indications; and mosliciguat, an inhaled sGC activator in\ndevelopment for pulmonary hypertension associated with interstitial lung\ndisease. We advance our pipeline by creating nimble subsidiaries or\n“Vants” to develop and commercialize our medicines and technologies. For\nmore information, visit www.roivant.com.\n\nRoivant Forward-Looking Statements \nThis press release contains forward-looking statements. Statements in this\npress release may include statements that are not historical facts and are\nconsidered forward-looking within the meaning of Section 27A of the Securities\nAct of 1933, as amended (the “Securities Act”), and Section 21E of the\nSecurities Exchange Act of 1934, as amended (the “Exchange Act”), which\nare usually identified by the use of words such as “anticipate,”\n“believe,” “continue,” “could,” “estimate,” “expect,”\n“intends,” “may,” “might,” “plan,” “possible,”\n“potential,” “predict,” “project,” “should,” “would” and\nvariations of such words or similar expressions. The words may identify\nforward-looking statements, but the absence of these words does not mean that\na statement is not forward-looking. We intend these forward-looking statements\nto be covered by the safe harbor provisions for forward-looking statements\ncontained in Section 27A of the Securities Act and Section 21E of the Exchange\nAct.\n\nOur forward-looking statements include, but are not limited to, statements\nregarding our or our management team’s expectations, hopes, beliefs,\nintentions or strategies regarding the future, and statements that are not\nhistorical facts, including statements about the clinical and therapeutic\npotential of our product and product candidates, the availability and success\nof topline results from our ongoing clinical trials, the timing of potential\nregulatory approvals for our product and product candidates, any commercial\npotential of our product and product candidates following applicable\nregulatory approvals and the outcome of any pending litigation. In addition,\nany statements that refer to projections, forecasts or other characterizations\nof future events, results or circumstances, including any underlying\nassumptions, are forward-looking statements. Actual results may differ\nmaterially from those contemplated in these statements due to a variety of\nrisks, uncertainties and other factors.\n\nAlthough we believe that our plans, intentions, expectations and strategies as\nreflected in or suggested by those forward-looking statements are reasonable,\nwe can give no assurance that the plans, intentions, expectations or\nstrategies will be attained or achieved. Furthermore, actual results may\ndiffer materially from those described in the forward-looking statements and\nwill be affected by a number of risks, uncertainties and assumptions,\nincluding, but not limited to, those risks set forth in the Risk Factors\nsection of our filings with the U.S. Securities and Exchange Commission.\nMoreover, we operate in a very competitive and rapidly changing environment in\nwhich new risks emerge from time to time. These forward-looking statements are\nbased upon the current expectations and beliefs of our management as of the\ndate of this press release, and are subject to certain risks and uncertainties\nthat could cause actual results to differ materially from those described in\nthe forward-looking statements. Except as required by applicable law, we\nassume no obligation to update publicly any forward-looking statements,\nwhether as a result of new information, future events or otherwise.\n\nContacts:\nInvestors\nKeyur Parekh\nkeyur.parekh@roivant.com\n\nMedia\nStephanie Lee\nstephanie.lee@roivant.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f1a5db68-ee4f-437f-b4e6-2b840ae6a536)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-21T11:00:01.116802038Z","server_sent_at_ms":1792580401116},"received_at":"2026-10-21T11:00:01.175Z","source_url":null},"analysis":{"id":"163252","press_release_id":"175231","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Roivant will report fiscal Q2 results (quarter ended September 30, 2026) and provide a business update on a conference call at 8:00 a.m. ET on Monday, November 9, 2026.\n\nThe company also scheduled an investor day for Wednesday, December 9, 2026, with in-person and webcast attendance available via registration.\n\nThe release contains no financial figures or pipeline news; it is a routine scheduling announcement.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Calendar marker only -- note the Nov 9 earnings date and Dec 9 investor day for event tracking."},"keyFigures":{},"namedEntities":{"people":[{"name":"Keyur Parekh","role":"Investor relations contact"},{"name":"Stephanie Lee","role":"Media contact"}],"products":["LISRAYA (brepocitinib)","IMVT-1402","mosliciguat"],"companies":[{"name":"Roivant","ticker":"ROIV","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Boilerplate scheduling notice for a Q2 earnings call and an investor day. No results, guidance, or business developments disclosed."},"tickerRelevance":{"others":[],"primary":"ROIV"},"globalImportance":8,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap biotech","eventGravity":"earnings-date-notice","issuerAuthored":true,"retailFavoriteBoost":"moderate -- ROIV has some retail following"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Roivant will report fiscal Q2 results (quarter ended September 30, 2026) and provide a business update on a conference call at 8:00 a.m. ET on Monday, November 9, 2026.\n\nThe company also scheduled an investor day for Wednesday, December 9, 2026, with in-person and webcast attendance available via registration.\n\nThe release contains no financial figures or pipeline news; it is a routine scheduling announcement.","key_figures":{},"named_entities":{"people":[{"name":"Keyur Parekh","role":"Investor relations contact"},{"name":"Stephanie Lee","role":"Media contact"}],"products":["LISRAYA (brepocitinib)","IMVT-1402","mosliciguat"],"companies":[{"name":"Roivant","ticker":"ROIV","relationship":"filer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-21T11:00:09.649Z","global_importance":8,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap biotech","eventGravity":"earnings-date-notice","issuerAuthored":true,"retailFavoriteBoost":"moderate -- ROIV has some retail following"}},"durationMs":3882,"modelName":"glm-5.3-flashx"}}